Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02554786
Other study ID # CQVM149B2301
Secondary ID 2015-002529-21
Status Completed
Phase Phase 3
First received
Last updated
Start date December 29, 2015
Est. completion date June 28, 2019

Study information

Verified date February 2020
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of the trial is to evaluate the efficacy and safety of two different doses of QMF149 (QMF149 150/160 µg and QMF149 150/320 µg via Concept1) over two respective MF doses (MF 400 µg and MF 800 µg via Twisthaler® (total daily dose)) in poorly controlled asthmatic participants as determined by pulmonary function testing, and effects on asthma control


Recruitment information / eligibility

Status Completed
Enrollment 2216
Est. completion date June 28, 2019
Est. primary completion date November 21, 2018
Accepts healthy volunteers No
Gender All
Age group 12 Years to 75 Years
Eligibility Inclusion Criteria:

- Participants with a diagnosis of asthma, for a period of at least 1 year prior to Visit 1 (Screening)

- Participants who have used medium or high dose inhaled corticosteroids (ICS) or low dose of long acting beta-2 agonist (LABA)/ICS combinations for asthma for at least 3 months and at stable doses for at least 1 month prior to Visit 1

- Participants must have ACQ-7 score = 1.5 at Visit 101 and at Visit 102 (prior to double-blind treatment) and qualify for treatment with medium or high dose LABA/ICS

- Pre-bronchodilator = 50% Forced expiratory volume in 1 second (FEV1) of < 85 % of the predicted normal value for the participants after withholding bronchodilators at both Visit 101 and 102, according to American Thoracic Society/European Respiratory Society (ATS/ERS) criteria.

- Withholding period of bronchodilators prior to spirometry: short acting beta-2 agonist (SABA) for = 6 hours and FDC or free combinations of ICS/LABA for = 48 hours, short acting anticholinergics (SAMA) for = 8 hours, xanthines >=07 days

- A one-time repeat/re-testing of percent predicted FEV1 (prebronchodilator FEV1) is allowed at Visit 101 and at Visit 102.

Spacer devices are permitted for reversibility testing only.

-Participants who demonstrate an increase in FEV1 of 12% and 200 mL within 30 minutes after administration of 400 µg salbutamol/360 µg albuterol (or equivalent dose) at Visit 101 All participants must perform a reversibility test at Visit 101

If reversibility is not demonstrated at Visit 101:

- Reversibility should be repeated once-

- Participants may be permitted to enter the study with historical evidence of reversibility that was performed according to ATS/ERS guidelines within 2 years prior to Visit 1

- Alternatively, participants may be permitted to enter the study with a historical positive bronchoprovocation test that was performed within 2 years prior to Visit 1.

Exclusion Criteria:

- Participants who have smoked or inhaled tobacco products within the 6 month period prior to Visit 1, or who have a smoking history of greater than 10 pack years. This includes use of nicotine inhalers such as e-cigarettes at the time of Visit 1

- Participants who have had an asthma attack/exacerbation requiring systemic steroids or hospitalization or emergency room visit within 6 weeks of Visit 1 (Screening)

- Participants who have ever required intubation for a severe asthma attack/exacerbation.

- Participants who have a clinical condition which is likely to be worsened by ICS administration (e.g. glaucoma, cataract and fragility fractures) who are according to investigator's medical judgment at risk participating in the study).

- Participants who have had a respiratory tract infection or asthma worsening as determined by the investigator within 4 weeks prior to Visit 1 (Screening) or between Visit 1 and Visit 102. Participants may be re-screened 4 weeks after recovery from their respiratory tract infection or asthma worsening.

- Participants with a history of chronic lung diseases other than asthma, including (but not limited to) Chronic Obstructive Pulmonary Disease (COPD), sarcoidosis, interstitial lung disease, cystic fibrosis, clinically significant bronchiectasis and active tuberculosis.

- Participants with severe narcolepsy and/or insomnia.

- Participants who have a clinically significant electrocardiogram (ECG) abnormality at Visit 101 (Start of Run- In epoch) and at any time between Visit 101 and Visit 102 (including unscheduled ECG). ECG evidence of myocardial infarction at Visit 101 (via central reader) should be clinically assessed by the investigator with supportivedocumentation

- Participants with a history of hypersensitivity to lactose, any of the study drugs or to similar drugs within the class including untoward reactions to sympathomimetic amines or inhaled medication or any component thereof

- Participants who have not achieved an acceptable spirometry results at Visit 101 in accordance with ATS/ERS criteria for acceptability and repeatability (rescreening allowed only once).

Repeat spirometry may be allowed once in an ad-hoc visit if the spirometry did not qualify due to ATS/ERS criteria. If the participant fails the repeat assessment, the participant may be rescreened once

- Participants on Maintenance Immunotherapy (desensitization) for allergies or less than 3 months prior to Visit 101 or participants on Maintenance Immunotherapy for more than 3 months prior to Visit 101 but expected to change throughout the course of the study.

- Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception during dosing of study treatment and for 30 days after stopping of study treatment.

- Long acting muscarinic antagonist (LAMA) use within 3 months prior to Visit 101

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Indacaterol acetate/Mometasone furoate

Mometasone furoate

Salmeterol xinafoate/fluticasone propionate


Locations

Country Name City State
Bulgaria Novartis Investigative Site Pleven
Bulgaria Novartis Investigative Site Plovdiv
Bulgaria Novartis Investigative Site Plovdiv BGR
Bulgaria Novartis Investigative Site Ruse
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Sofia
Bulgaria Novartis Investigative Site Stara Zagora
Bulgaria Novartis Investigative Site Troyan
Bulgaria Novartis Investigative Site Varna BGR
Bulgaria Novartis Investigative Site Vidin BGR
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing
China Novartis Investigative Site Beijing Beijing
China Novartis Investigative Site Beijing Beijing
China Novartis Investigative Site Chang Chun Jilin
China Novartis Investigative Site Changsha Hunan
China Novartis Investigative Site Chengdu Sichuan
China Novartis Investigative Site Chengdu
China Novartis Investigative Site Chongqing
China Novartis Investigative Site Fuzhou Fujian
China Novartis Investigative Site Guang Zhou Guangdong
China Novartis Investigative Site Guang Zhou
China Novartis Investigative Site Guangzhou
China Novartis Investigative Site Guangzhou
China Novartis Investigative Site Haikou Hainan
China Novartis Investigative Site Hangzhou Zhejiang
China Novartis Investigative Site Hangzhou Zhejiang
China Novartis Investigative Site Nanchang
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Nanjing Jiangsu
China Novartis Investigative Site Shanghai Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shanghai
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shenyang Liaoning
China Novartis Investigative Site Shijiazhuang Hebei
China Novartis Investigative Site Suzhou Jiangsu
China Novartis Investigative Site Tianjin
China Novartis Investigative Site Wuhan Hubei
China Novartis Investigative Site Xian Shanxi
Croatia Novartis Investigative Site Petrinja
Croatia Novartis Investigative Site Rijeka
Croatia Novartis Investigative Site Varazdin HRV
Croatia Novartis Investigative Site Zadar
Croatia Novartis Investigative Site Zagreb
Croatia Novartis Investigative Site Zagreb HRV
Czechia Novartis Investigative Site Beroun Czech Republic
Czechia Novartis Investigative Site Boskovice Czech Republic
Czechia Novartis Investigative Site Breclav
Czechia Novartis Investigative Site Cesky Krumlov
Czechia Novartis Investigative Site Jablonec nad Nisou Czech Republic
Czechia Novartis Investigative Site Jindrichuv Hradec Czech Republic
Czechia Novartis Investigative Site Kurim Czech Republic
Czechia Novartis Investigative Site Kutna Hora
Czechia Novartis Investigative Site Novy Bor
Czechia Novartis Investigative Site Ostrava CZE
Czechia Novartis Investigative Site Plzen CZE
Czechia Novartis Investigative Site Plzen
Czechia Novartis Investigative Site Praha Czech Republic
Czechia Novartis Investigative Site Praha 8
Czechia Novartis Investigative Site Rokycany
Czechia Novartis Investigative Site Tabor
Czechia Novartis Investigative Site Teplice CZE
Czechia Novartis Investigative Site Teplice Czech Republic
Czechia Novartis Investigative Site Varnsdorf Czech Republic
Egypt Novartis Investigative Site Alexandria
Estonia Novartis Investigative Site Tallinn
Estonia Novartis Investigative Site Tartu
Germany Novartis Investigative Site Ahlen
Germany Novartis Investigative Site Bamberg
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Berlin
Germany Novartis Investigative Site Bochum
Germany Novartis Investigative Site Boehlen
Germany Novartis Investigative Site Bonn
Germany Novartis Investigative Site Delitzsch
Germany Novartis Investigative Site Dresden
Germany Novartis Investigative Site Dueren
Germany Novartis Investigative Site Düsseldorf
Germany Novartis Investigative Site Erlangen
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Frankfurt
Germany Novartis Investigative Site Furstenwalde
Germany Novartis Investigative Site Halle
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hannover
Germany Novartis Investigative Site Hochstadt
Germany Novartis Investigative Site Kassel
Germany Novartis Investigative Site Koblenz Rheinland-Pfalz
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Leipzig
Germany Novartis Investigative Site Lubeck
Germany Novartis Investigative Site Ludwigsburg
Germany Novartis Investigative Site Marburg
Germany Novartis Investigative Site Mittweida
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Neu Isenburg
Germany Novartis Investigative Site Neuss
Germany Novartis Investigative Site Peine Niedersachsen
Germany Novartis Investigative Site Potsdam
Germany Novartis Investigative Site Potsdam
Germany Novartis Investigative Site Rheine
Germany Novartis Investigative Site Rudersdorf
Germany Novartis Investigative Site Schleswig
Germany Novartis Investigative Site Schwedt
Germany Novartis Investigative Site Weinheim
Germany Novartis Investigative Site Witten
Guatemala Novartis Investigative Site Ciudad Gautemala
Guatemala Novartis Investigative Site Guatemala City GTM
Guatemala Novartis Investigative Site Guatemala City GTM
Guatemala Novartis Investigative Site Guatemala City
Guatemala Novartis Investigative Site Guatemala City
Guatemala Novartis Investigative Site Guatemala City
Hungary Novartis Investigative Site Balassagyarmat
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest
Hungary Novartis Investigative Site Budapest HUN
Hungary Novartis Investigative Site Budapest HUN
Hungary Novartis Investigative Site Budapest HUN
Hungary Novartis Investigative Site Budapest HUN
Hungary Novartis Investigative Site Cegled
Hungary Novartis Investigative Site Csorna
Hungary Novartis Investigative Site Dombovar
Hungary Novartis Investigative Site Godollo
Hungary Novartis Investigative Site Gyor HUN
Hungary Novartis Investigative Site Hajdunanas HUN
Hungary Novartis Investigative Site Hatvan
Hungary Novartis Investigative Site Komarom
Hungary Novartis Investigative Site Mako HUN
Hungary Novartis Investigative Site Miskolc HUN
Hungary Novartis Investigative Site Miskolc
Hungary Novartis Investigative Site Mosdos
Hungary Novartis Investigative Site Puspokladany HUN
Hungary Novartis Investigative Site Szarvas
Hungary Novartis Investigative Site Szazhalombatta HUN
Hungary Novartis Investigative Site Szeged
Hungary Novartis Investigative Site Szeged
Hungary Novartis Investigative Site Szigetvar
Hungary Novartis Investigative Site Szombathely
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Ahmedabad Gujarat
India Novartis Investigative Site Hyderabad Telangana
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Jaipur Rajasthan
India Novartis Investigative Site Kozhikode Kerala
India Novartis Investigative Site Lucknow Uttar Pradesh
India Novartis Investigative Site Mohali Punjab
India Novartis Investigative Site Mumbai Maharashtra
India Novartis Investigative Site Mysore Karnataka
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site Nagpur Maharashtra
India Novartis Investigative Site New Delhi Delhi
India Novartis Investigative Site New Delhi
India Novartis Investigative Site Pune Maharashtra
India Novartis Investigative Site Vadodara Gujarat
Ireland Novartis Investigative Site County Limerick
Ireland Novartis Investigative Site Dublin
Ireland Novartis Investigative Site Wilton Cork
Japan Novartis Investigative Site Atsugi-city Kanagawa
Japan Novartis Investigative Site Chuo ku Tokyo
Japan Novartis Investigative Site Chuou-ku Tokyo
Japan Novartis Investigative Site Fukuoka-city Fukuoka
Japan Novartis Investigative Site Himeji-city Hyogo
Japan Novartis Investigative Site Himeji-city Hyogo
Japan Novartis Investigative Site Ichihara-city Chiba
Japan Novartis Investigative Site Itabashi-ku Tokyo
Japan Novartis Investigative Site Kasuga-city Fukuoka
Japan Novartis Investigative Site Kawasaki-city Kanagawa
Japan Novartis Investigative Site Kishiwada-city Osaka
Japan Novartis Investigative Site Koshigaya-city Saitama
Japan Novartis Investigative Site Naka-gun Ibaraki
Japan Novartis Investigative Site Obihiro-city Hokkaido
Japan Novartis Investigative Site Okayama-city Okayama
Japan Novartis Investigative Site Osaka city Osaka
Japan Novartis Investigative Site Sendai-city Miyagi
Japan Novartis Investigative Site Setagaya-Ku Tokyo
Japan Novartis Investigative Site Shinjuku-ku Tokyo
Japan Novartis Investigative Site Shinjuku-ku Tokyo
Japan Novartis Investigative Site Takatsuki-city Osaka
Japan Novartis Investigative Site Tokyo Shibuya Ku
Japan Novartis Investigative Site Toshima ku Tokyo
Japan Novartis Investigative Site Toshima-ku Tokyo
Japan Novartis Investigative Site Toyonaka-city Osaka
Japan Novartis Investigative Site Yanagawa-city Fukuoka
Japan Novartis Investigative Site Yao-city Osaka
Japan Novartis Investigative Site Yokohama Kanagawa
Japan Novartis Investigative Site Yokohama-city Kanagawa
Japan Novartis Investigative Site Yokohama-city Kanagawa
Japan Novartis Investigative Site Yokohama-city Kanagawa
Korea, Republic of Novartis Investigative Site Bucheon-Si Gyeonggi-Do
Korea, Republic of Novartis Investigative Site Bundang Gu Gyeonggi Do
Korea, Republic of Novartis Investigative Site Cheongju si Chungcheongbuk Do
Korea, Republic of Novartis Investigative Site Incheon
Korea, Republic of Novartis Investigative Site Seoul Korea
Korea, Republic of Novartis Investigative Site Seoul Korea
Korea, Republic of Novartis Investigative Site Seoul Seocho Gu
Korea, Republic of Novartis Investigative Site Wonju Gangwon-do
Latvia Novartis Investigative Site Daugavpils
Latvia Novartis Investigative Site Riga
Latvia Novartis Investigative Site Riga
Latvia Novartis Investigative Site Riga LV
Lithuania Novartis Investigative Site Kaunas LTU
Lithuania Novartis Investigative Site Kaunas
Lithuania Novartis Investigative Site Siauliai
Lithuania Novartis Investigative Site Utena
Lithuania Novartis Investigative Site Vilnius
Mexico Novartis Investigative Site Ciudad de Mexico Distrito Federal
Mexico Novartis Investigative Site Mexicali Baja California
Mexico Novartis Investigative Site Mexico Distrito Federal
Mexico Novartis Investigative Site Mexico
Poland Novartis Investigative Site Aleksandrow Odzki
Poland Novartis Investigative Site Biaystok
Poland Novartis Investigative Site Bielsko-Biala
Poland Novartis Investigative Site Elblag
Poland Novartis Investigative Site Inowroclaw
Poland Novartis Investigative Site Katowice
Poland Novartis Investigative Site Krakow
Poland Novartis Investigative Site Lodz
Poland Novartis Investigative Site Lodz POL
Poland Novartis Investigative Site Ostrow Wielkopolski
Poland Novartis Investigative Site Sopot
Poland Novartis Investigative Site Warsaw
Poland Novartis Investigative Site Wejherowo POL
Poland Novartis Investigative Site Zawadzkie
Romania Novartis Investigative Site Arad
Romania Novartis Investigative Site Bacau
Romania Novartis Investigative Site Bragadiru
Romania Novartis Investigative Site Braila
Romania Novartis Investigative Site Brasov
Romania Novartis Investigative Site Bucharest
Romania Novartis Investigative Site Bucharest ROM
Romania Novartis Investigative Site Bucuresti
Romania Novartis Investigative Site Bucuresti
Romania Novartis Investigative Site Cluj Napoca
Romania Novartis Investigative Site Cluj Napoca
Romania Novartis Investigative Site Cluj-Napoca
Romania Novartis Investigative Site Codlea
Romania Novartis Investigative Site Constanta Jud. Constanta
Romania Novartis Investigative Site Craiova Jud.Dolj
Romania Novartis Investigative Site Craiova ROM
Romania Novartis Investigative Site Craiova ROM
Romania Novartis Investigative Site Craiova
Romania Novartis Investigative Site Deva ROM
Romania Novartis Investigative Site Iasi Jud Iasi
Romania Novartis Investigative Site Ramnicu Valcea
Romania Novartis Investigative Site Suceava
Romania Novartis Investigative Site Targu Mures
Romania Novartis Investigative Site Timisoara ROM
Romania Novartis Investigative Site Timisoara Timis
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Chelyabinsk
Russian Federation Novartis Investigative Site Kazan
Russian Federation Novartis Investigative Site Krasnoyarsk
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site N.Novgorod
Russian Federation Novartis Investigative Site Novosibirsk
Russian Federation Novartis Investigative Site Novosibirsk
Russian Federation Novartis Investigative Site Penza
Russian Federation Novartis Investigative Site Petrozavodsk
Russian Federation Novartis Investigative Site Pyatigorsk
Russian Federation Novartis Investigative Site Ryazan
Russian Federation Novartis Investigative Site Ryazan
Russian Federation Novartis Investigative Site Saint Petersburg
Russian Federation Novartis Investigative Site Saint-Petersburg
Russian Federation Novartis Investigative Site Saratov
Russian Federation Novartis Investigative Site Saratov
Russian Federation Novartis Investigative Site Smolensk
Russian Federation Novartis Investigative Site Smolensk
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St Petersburg
Russian Federation Novartis Investigative Site St-Petersburg
Russian Federation Novartis Investigative Site St-Petersburg
Russian Federation Novartis Investigative Site St.Petersburg
Russian Federation Novartis Investigative Site Stavropol
Russian Federation Novartis Investigative Site Volgograd
Russian Federation Novartis Investigative Site Vologodonsk
Russian Federation Novartis Investigative Site Yaroslavl
Russian Federation Novartis Investigative Site Yaroslavl
Russian Federation Novartis Investigative Site Yaroslavl
Russian Federation Novartis Investigative Site Yaroslavl
Russian Federation Novartis Investigative Site Yekaterinburg
Serbia Novartis Investigative Site Belgrade
Serbia Novartis Investigative Site Beograd
Serbia Novartis Investigative Site Kragujevac
Serbia Novartis Investigative Site Nis
Serbia Novartis Investigative Site Sremska Kamenica
Slovakia Novartis Investigative Site Bardejov Slovak Republic
Slovakia Novartis Investigative Site Bardejov
Slovakia Novartis Investigative Site Bojnice Slovak Republic
Slovakia Novartis Investigative Site Bratislava Slovak Republic
Slovakia Novartis Investigative Site Bratislava
Slovakia Novartis Investigative Site Cadca
Slovakia Novartis Investigative Site Humenne Slovak Republic
Slovakia Novartis Investigative Site Ilava
Slovakia Novartis Investigative Site Komarno
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Kosice
Slovakia Novartis Investigative Site Kosice Slovak Republic
Slovakia Novartis Investigative Site Kralovsky Chlmec
Slovakia Novartis Investigative Site Levice
Slovakia Novartis Investigative Site Liptovsky Mikulas
Slovakia Novartis Investigative Site Námestovo Slovensko
Slovakia Novartis Investigative Site Nitra Slovak Republic
Slovakia Novartis Investigative Site Poprad SVK
Slovakia Novartis Investigative Site Presov
Slovakia Novartis Investigative Site Prievidza
Slovakia Novartis Investigative Site Skalica Slovak Republic
Slovakia Novartis Investigative Site Spisska Nova Ves Slovak Republic
Slovakia Novartis Investigative Site Stropkov Slovak Republic
Slovakia Novartis Investigative Site Surany Slovak Republic
Slovakia Novartis Investigative Site Topolcany
Slovakia Novartis Investigative Site Velky Meder Slovak Republic
Slovakia Novartis Investigative Site Zilina
Slovakia Novartis Investigative Site Zilina
South Africa Novartis Investigative Site Belleville
South Africa Novartis Investigative Site Berea Durban
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Cape Town
South Africa Novartis Investigative Site Panorama Western Cape
United Kingdom Novartis Investigative Site Blackpool
United Kingdom Novartis Investigative Site Bristol South Gloucestershire
United Kingdom Novartis Investigative Site Denbighshire
United Kingdom Novartis Investigative Site Faringdon Oxfordshire
United Kingdom Novartis Investigative Site Fowey Cornwall
United Kingdom Novartis Investigative Site Glasgow
United Kingdom Novartis Investigative Site Liskeard Cornwall
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Rotherham
United Kingdom Novartis Investigative Site Torpoint Cornwall
United Kingdom Novartis Investigative Site Wiltshire
United States Novartis Investigative Site Baltimore Maryland
United States Novartis Investigative Site Bellevue Nebraska
United States Novartis Investigative Site Birmingham Alabama
United States Novartis Investigative Site Boerne Texas
United States Novartis Investigative Site Cortland New York
United States Novartis Investigative Site Denver Colorado
United States Novartis Investigative Site El Paso Texas
United States Novartis Investigative Site Greenfield Wisconsin
United States Novartis Investigative Site Las Vegas Nevada
United States Novartis Investigative Site Los Angeles California
United States Novartis Investigative Site Medford Oregon
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site North Charleston South Carolina
United States Novartis Investigative Site North Dartmouth Massachusetts
United States Novartis Investigative Site Oklahoma City Oklahoma
United States Novartis Investigative Site Orange California
United States Novartis Investigative Site Pittsburgh Pennsylvania
United States Novartis Investigative Site Portland Oregon
United States Novartis Investigative Site Riverside California
United States Novartis Investigative Site Saint Louis Missouri
United States Novartis Investigative Site San Diego California
United States Novartis Investigative Site San Jose California
United States Novartis Investigative Site Skillman New Jersey
United States Novartis Investigative Site Stockton California
United States Novartis Investigative Site Tallahassee Florida
United States Novartis Investigative Site Tulsa Oklahoma
United States Novartis Investigative Site Waldorf Maryland
United States Novartis Investigative Site Westminster California
United States Novartis Investigative Site Winter Park Florida

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Bulgaria,  China,  Croatia,  Czechia,  Egypt,  Estonia,  Germany,  Guatemala,  Hungary,  India,  Ireland,  Japan,  Korea, Republic of,  Latvia,  Lithuania,  Mexico,  Poland,  Romania,  Russian Federation,  Serbia,  Slovakia,  South Africa,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. 26 weeks
Secondary Asthma Control Questionnaire (ACQ-7) at Weeks 4, 12, 26 and 52 The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means > 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means < 50% of predicted FEV1). The total score was calculated as the mean of all questions. Weeks 4, 12, 26 and 52
Secondary Trough FEV1 at Week 52 Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Week 52
Secondary Pre-dose FEV1 at Weeks 4 and 12 Pre-dose trough FEV1 is defined as average of the two FEV1 measurements taken 45 min and 15 min pre evening dose. It was assessed by performing spirometric assessment. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Weeks 4 (Day 30) and 12 (Day 86)
Secondary Post Dose FEV1 (5 Minutes-1 Hour) Post-dose FEV1 measurements were analyzed at 5 minutes, 15 minutes, 30 minutes and 1 hour. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Up to Week 52 (Day 364)
Secondary Trough Forced Vital Capacity (FVC) FVC is the total amount of air exhaled during the FEV test. Trough FVC is defined as average of the two FVC measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment. Up to Week 52 (Day 365)
Secondary Trough Forced Expiratory Flow (FEF)Between 25% and 75% of FVC (FEF25-75) FEF is the flow (or speed) of air coming out of the lung during the middle portion of a forced expiration. Trough FEF25-75% is defined as average of the two FEF25-75% measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. It was assessed by performing spirometric assessment. Up to Week 52 (Day 365)
Secondary Change From Baseline in Morning and Evening Peak Expiratory Flow Rate (PEF) Over 26 and 52 Weeks of Treatment PEF is a person's maximum speed of expiration. All the participants were instructed to record PEF twice daily using a mini Peak Flow Meter device, once in the morning (before taking the morning dose) and once approximately 12 h later in the evening (before taking the evening dose). At each timepoint, the participant was instructed to perform 3 consecutive manoeuvres within 10 minutes. These PEF values were captured in the e-PEF/diary. The best of 3 values were used. Up to Weeks 26 and 52
Secondary Percentage of Participants Achieving the Minimal Important Difference (MID) ACQ = 0.5 at Weeks 26 and 52 Change from baseline in ACQ-7 scores of = 0.5 was defined as minimal clinically important difference and were considered clinically meaningful. The ACQ-7 measured asthma symptom control and consists of 7 items: 5 on symptom assessment, 1 on rescue bronchodilator use and 1 on airway calibre (FEV1 % predicted). All 7 questions of the ACQ-7 were equally weighted. Items 1-5 were scored along a 7-point response scale, where 0 = totally controlled and 6 = severely uncontrolled. Item 6 is scored between 0 = no rescue medication and 6 = More than 16 puffs/inhalations most days. The 7th item was scored by the investigator based on the FEV1 % predicted from the masterscope at the site (i.e., Score = 0 means > 95% of predicted FEV1, 1 = 90 - 95%, 2 = 80 - 89%, 3 = 70 - 79%, 4 = 60 - 69%, 5 = 50 - 59%, and Score = 6 means < 50% of predicted FEV1). The total score was calculated as the mean of all questions Weeks 26 (Day 183) and 52 (Day 364)
Secondary Change From Baseline in Percentage of Asthma Symptoms Free Days All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. Asthma symptoms free days are days with no daytime symptoms, no night-time awakenings and no symptoms on awakening. The daytime asthma symptom score was based on the daily e-diary recordings by participants with respect to shortness of breath, wheeze, cough, chest tightness, and impact on usual daily activities due to symptoms. Up to Week 52
Secondary Change Form Baseline in Percentage of Days With no Daytime Symptoms All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. For days with no daytime symptoms, all 5 evening questions must have a score = 0 with respect to shortness of breath, wheeze, cough, chest tightness and impact on usual daily activities due to symptoms, each with scores from 0 (no problems) to 4 (very severe problems). Up to Week 52
Secondary Change From Baseline in Percentage of Nights With no Night-time Awakenings All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for nights with no night-time awakenings was "How did you sleep last night?" had to be answered with "I did not wake up because of any breathing problems" with scores from 0 (no problem)-4 (very severe problems). Up to Week 52
Secondary Change Form Baseline in Percentage of Mornings With no Symptoms on Awakening All participants were provided with an electronic diary (e-Diary) to record clinical symptoms. They were instructed to routinely complete the e-Diary twice daily at the same time each morning and again approximately 12 hours later in the evening. The e-Diary was reviewed at each visit until study completion. The question asked for mornings with no symptoms on awakening was "Did you have asthma symptoms upon awakening in the morning?" to be answered with "None" with scores from 0 (no problem)-4 (very severe problems). Up to Week 52
Secondary Rescue Medication Usage All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. The number of puffs of rescue medication during the past 12 hours is recorded twice (morning/evening) by the participant prior to taking study medication. The mean daily number of puffs of rescue medication use will be calculated for each participant, done separately for morning (night-time), evening (daytime), and daily (night-time plus daytime) rescue medication use Up to Weeks 26 and 52
Secondary Time to First Asthma Exacerbation by Exacerbation Category The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe. Up to Week 52
Secondary Time to First Hospitalization for Asthma Exacerbation The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe. Up to Week 52
Secondary Annual Rate of Asthma Exacerbations by Exacerbation Category The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe. Up to Week 52
Secondary Duration in Days of Asthma Exacerbations by Exacerbation Category The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe. Up to Week 52
Secondary Percentage of Participants With at Least One Asthma Exacerbation by Exacerbation Category The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe. Up to Week 52
Secondary Time in Days to Permanent Discontinuation of Study Medication Due to Asthma Exacerbations The exacerbation categories were: All (mild, moderate and severe) and combination of moderate or severe and severe. Up to Week 52
Secondary Percentage of Participants Who Permanently Discontinued Study Medication Due to Asthma Exacerbations Up to Week 52
Secondary Total Amounts of Systemic Corticosteroids (in Doses) Used to Treat Asthma Exacerbations The treatment of asthma exacerbations including the initiation of systemic corticosteroids were done according to investigator's or treating physician's medical judgement and in line with national and international recommendations. If systemic corticosteroids were required, a participant could return to the study after successfully completing a taper of approximately 7-10 days. Up to Week 52
Secondary Change From Baseline in Percentage of Rescue Medication Free Days All participants were given salbutamol/albuterol to use as rescue medication throughout the study along with e-Diary to record rescue medication use. Rescue medication free days is defined as any day where the participant did not use any puffs of rescue medication during daytime and night-time. Up to Weeks 26 and 52
Secondary Asthma Quality of Life Questionnaire (AQLQ) AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments that are most important to patients with asthma, with a recall time of two weeks and each question to be answered on a 7-point scale (1-totally limited/problems all the time, 7-not at all limited/no problems). It consists of 4 domains:
Symptoms = Mean of Items 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 29, 30 (12 items)
Activity limitation = Mean of Items 1, 2, 3, 4, 5, 11, 19, 25, 28, 31, 32 (11 items)
Emotional function = Mean of Items 7, 13, 15, 21, 27 (5 items)
Environmental stimuli = Mean of Items 9, 17, 23, 26 (4 items)
Overall Score = Mean of Items 1 to 32 (32 items)
Up to Week 52 (Day 364)
Secondary Trough FEV1 Measured After 26 Weeks of Treatment Trough FEV1 was assessed by performing spirometric assessment. It is defined as average of the two FEV1 measurements taken 23 hr 15 min and 23 hr 45 min post-evening dose. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation, measured through spirometry testing. Week 26
Secondary Percentage of Participants With Composite Endpoint of Serious Asthma Outcomes A composite endpoint of serious asthma outcomes is defined as asthma-related hospitalization, asthma-related intubation, or asthma-related death and was reviewed by the Adjudication Committee. Up to Week 52
Secondary Percentage of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) An AE is any untoward medical occurrence (i.e., any unfavorable and unintended sign including abnormal laboratory findings, symptom or disease) in a participant or clinical investigation participant after providing written informed consent for participation in the study. An SAE is defined as any adverse event (appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s) or medical conditions(s) which meets any one of the following criteria: is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant, i.e. defined as an event that jeopardizes the participants or may require medical or surgical intervention. Approximately up to 56 weeks
See also
  Status Clinical Trial Phase
Terminated NCT04410523 - Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma Phase 2
Completed NCT04624425 - Additional Effects of Segmental Breathing In Asthma N/A
Active, not recruiting NCT03927820 - A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR) N/A
Completed NCT04617015 - Defining and Treating Depression-related Asthma Early Phase 1
Recruiting NCT03694158 - Investigating Dupilumab's Effect in Asthma by Genotype Phase 4
Terminated NCT04946318 - Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma Phase 2
Completed NCT04450108 - Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients N/A
Completed NCT03086460 - A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH) Phase 2
Completed NCT01160224 - Oral GW766944 (Oral CCR3 Antagonist) Phase 2
Completed NCT03186209 - Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE) Phase 3
Completed NCT02502734 - Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma Phase 3
Completed NCT01715844 - L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics Phase 1
Terminated NCT04993443 - First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036 Phase 1
Completed NCT02787863 - Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology Phase 4
Recruiting NCT06033833 - Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study Phase 2
Completed NCT03257995 - Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma. Phase 2
Completed NCT02212483 - Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients N/A
Recruiting NCT04872309 - MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
Withdrawn NCT01468805 - Childhood Asthma Reduction Study N/A
Recruiting NCT05145894 - Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device